Related Experiment Videos
Management of hepatitis C in human immunodeficiency virus-infected patients
1Division of Infectious and Tropical Diseases, IRCCS S. Matteo Hospital, University of Pavia, Italy. r.bruno@smatteo.pv.it
Insights
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection increases liver disease risks. Aggressive treatment, including antiretroviral therapy, is crucial for better outcomes in these complex cases.
Area of Science:
- Hepatology
- Infectious Diseases
- Virology
Background:
- Hepatitis C virus (HCV)-related liver disease is a growing concern in individuals with human immunodeficiency virus (HIV) co-infection.
- Liver-related mortality is increasing in HIV-HCV co-infected patients, necessitating aggressive treatment strategies.
- Current treatment options, including interferon/ribavirin and highly active antiretroviral therapy (HAART), require careful evaluation for safety and efficacy.
Purpose of the Study:
- To review the current understanding of managing HIV-HCV co-infection.
- To highlight the need for aggressive treatment approaches in co-infected patients.
- To emphasize the importance of a multidisciplinary approach for optimal patient outcomes.
Main Methods:
- Literature review on the management of HIV-HCV co-infection.
- Analysis of safety and efficacy data for HCV treatments in co-infected individuals.
- Discussion of HAART-associated hepatotoxicity concerns.
Main Results:
- Interferon/ribavirin safety and efficacy in HIV-HCV co-infected patients are under evaluation.
- Antiretroviral therapy should be offered to HIV-HCV co-infected patients despite hepatotoxicity concerns.
- Management of co-infected patients is complex and requires specialized care.
Conclusions:
- Aggressive treatment is warranted for HIV-HCV co-infected patients due to rising liver-related deaths.
- A multidisciplinary approach is essential for effective management and positive outcomes.
- Further research on treatment safety and efficacy in this population is needed.
Abstract:
Hepatitis C virus-related liver disease and its associated complications are steadily emerging health concerns in persons co-infected with human immunodeficiency virus. The increasing number of liver-related deaths in human immunodeficiency virus-hepatitis C virus co-infected individuals supports the compelling argument for more aggressive treatment in these patients. The safety and efficacy of interferon/ribavirin in human immunodeficiency virus/hepatitis C virus co-infected patients is currently under evaluation. Despite well-documented concern over highly active antiretroviral therapy-associated hepatotoxicity human immunodeficiency virus/hepatitis C virus co-infected patients should be offered antiretroviral therapy. Since management of co-infected patients is complex a multidisciplinary approach is needed in order to facilitate care and help patients to achieve a positive outcome.